AAAAAA
Results:
1-11
|
Results: 11
Authors:
Dumez, H
Guetens, G
De Boeck, G
Highley, M
Tjaden, UR
Maes, R
Hanauske, A
Van Oosterom, AT
de Bruijn, EA
Citation: H. Dumez et al., Quantitation of suspensions (MESED). Application of MESED-GC/MS in the quantitation of ifosfamide mustard in erythrocytes, plasma, and plasma water, J SEP SCI, 24(2), 2001, pp. 123-128
Authors:
Vansteenkiste, J
Gatzemeier, U
Manegold, C
Hanauske, A
Weynants, P
Bosquee, L
Blatter, J
Mansouri, K
von Pawel, J
Citation: J. Vansteenkiste et al., Gemcitabine plus etoposide in chemonaive extensive disease small-cell lungcancer: A multi-centre phase II study, ANN ONCOL, 12(6), 2001, pp. 835-840
Authors:
Smyth, J
Boneterre, ME
Schellens, J
Calvert, H
Greim, G
Wanders, J
Hanauske, A
Citation: J. Smyth et al., Activity of the dolastatin analogue, LU103793, in malignant melanoma, ANN ONCOL, 12(4), 2001, pp. 509-511
Authors:
Dent, S
Zee, B
Dancey, J
Hanauske, A
Wanders, J
Eisenhauer, E
Citation: S. Dent et al., Application of a new multinomial phase II stopping rule using response andearly progression, J CL ONCOL, 19(3), 2001, pp. 785-791
Authors:
Dumez, H
Highley, M
Guetens, G
De Boeck, G
Hanauske, A
van Oosterom, AT
Maes, RAA
de Bruijn, EA
Harper, P
Citation: H. Dumez et al., Erythrocytes and the transfer of anticancer drugs and metabolites: A possible relationship with therapeutic outcome, SEMIN ONCOL, 28(2), 2001, pp. 24-28
Authors:
Gamucci, T
Paridaens, R
Heinrich, B
Schellens, JH
Pavlidis, N
Verweij, J
Sessa, C
Kaye, S
Roelvink, M
Wanders, J
Hanauske, A
Citation: T. Gamucci et al., Activity and toxicity of GI147211 in breast, colorectal and non-small-celllung cancer patients: An EORTC-ECSG phase II clinical study, ANN ONCOL, 11(7), 2000, pp. 793-797
Authors:
Hanauske, A
Citation: A. Hanauske, New anticancer agent with minimal side effects has unique mechanism of action, ONCOLOGY-NY, 14(2), 2000, pp. 164-164
Authors:
Briasoulis, E
Judson, I
Pavlidis, N
Beale, P
Wanders, J
Groot, Y
Veerman, G
Schuessler, M
Niebch, G
Siamopoulos, K
Tzamakou, E
Rammou, D
Wolf, L
Walker, R
Hanauske, A
Citation: E. Briasoulis et al., Phase I trial of 6-hour infusion of glufosfamide, a new alkylating agent with potentially enhanced selectivity for tumors that overexpress transmembrane glucose transporters: A study of the European Organization for Researchand Treatment of Cancer Early Clinical Studies Group, J CL ONCOL, 18(20), 2000, pp. 3535-3544
Phase II trial of cystemustine, a new nitrosourea, as treatment of high-grade brain tumors in adults
Authors:
Roche, H
Cure, H
Adenis, A
Fargeot, P
Terret, C
Lentz, MA
Madelmont, JC
Fumoleau, P
Hanauske, A
Chollet, P
Citation: H. Roche et al., Phase II trial of cystemustine, a new nitrosourea, as treatment of high-grade brain tumors in adults, J NEURO-ONC, 49(2), 2000, pp. 141-145
Authors:
Cure, H
Souteyrand, P
Ouabdesselam, R
Roche, H
Ravaud, A
D'incan, M
Viens, P
Fargeot, P
Lentz, MA
Fumoleau, P
Hanauske, A
Chollet, P
Citation: H. Cure et al., Results of a phase II trial with cystemustine at 90 mg/m(2) as a first- orsecond-line treatment in advanced malignant melanoma: a trial of the EORTCClinical Studies Group, MELANOMA RE, 9(6), 1999, pp. 607-610
Authors:
Schoffski, P
Chollet, P
Ganser, A
Wiese, KH
Rambusch, E
de Vries, MJ
Hanauske, A
Citation: P. Schoffski et al., Complete response of a gastric primary after a short but toxic course of 'S-1', ANN ONCOL, 10(9), 1999, pp. 1117-1120
Risultati:
1-11
|